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Introduction: Prosthetic heart valve thrombosis (PHVT) is a major complication in 
patients with mechanical prosthetic heart valve which occurs primarily due to 
ineffective anticoagulation. This study aimed to evaluate the clinical profile of the 
patients presenting with PHVT undergoing fibrinolytic therapy and analyzing patients 
with respect to New York Heart Association (NYHA) functional class on presentation 
and its association with outcome of fibrinolytic therapy. 
Methods: This was prospective, observational study conducted from June, 2016 to 
April, 2018. Total 133 patients with prosthetic heart valve thrombosis were included.  
Routine blood investigations included complete hemogram, liver and renal function 
tests. Prothrombin time with INR was done on admission. The diagnosis of PHVT was 
assessed by cine-fluoroscopy (CF) and/or echocardiography 
(transthoracic/transesophageal). Follow-up at 6 months was scheduled for all patients. 
Results: All patients received fibrinolytic therapy in which 108 (81.2%) were treated 
with streptokinase and 25 (18.8%) were treated with urokinase. On presentation, 48.9% 
patients were in NYHA class III, 41.4% in NYHA class IV and 9.77% in NYHA class II. 
Fibrinolytic therapy was successful in 105 patients (78.9%) and it failed in 28 patients 
(21.1%). Mortality in NYHA class II was 0%, NYHA class III was 4.6% and in NYHA 
class IV was 23.6%. During 6 months follow up prosthetic heart valve thrombosis 
recurred in 12 (11.43%) patients. 
Conclusion: From our single center experience, fibrinolytic therapy is effective first line 
therapy for prosthetic heart valve thrombosis and NYHA functional class on 
presentation can predict the outcome of fibrinolytic therapy. 
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INTRODUCTION
Prosthetic heart valve thrombosis (PHVT) is a rare but 
often deadly complication of valve replacement related 
to morbidity and mortality after valve replacement. 
Globally, the prosthetic heart valve implantation rate is 
increasing 5-7% per year [1]. There is about 10% 
prevalence of left-sided PHVT, upon screening of 
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around 1000 post-operated patients [2]. The clinical 
presentation is variable and ranges from insidious 
dyspnea to cardiac arrest. It might be obstructive or non-
obstructive thrombosis [3]. Obstructive thrombosis is 
related with hemodynamic compromise and non-
obstructive thrombosis is usually asymptomatic or 
accidental identification. The obstruction of a 
mechanical prosthesis mostly necessitates aggressive 
treatment with surgery or fibrinolysis, as the 
administration of anticoagulants will generally be 
insufficient. Due to the absence of larger prospective 
studies, the choice of treatment for PHVT remains 
controversial.  
As per the American College of Cardiology/ American 
Heart Association guidelines, surgery should be the 
preferred treatment strategy for left-sided PHVT. 
Fibrinolytic therapy should be administered only to 
patients with poor functional class (NYHA class III or 
IV), and those with high surgical risk or 
contraindications to surgery. If the prior heparin 
treatment fails to manage the patients, fibrinolytic 
therapy can also be considered in such patients with 
good functional class (NYHA class-I or II) and a small 
thrombus load. Several studies have been done for 
prediction of the success rates and improving the risk 
stratification for patients undergoing fibrinolysis [2, 4, 
5].  
In some studies, NYHA functional class, level of 
obstruction, valve location (left- or right-sided) and 
thrombus size were recognized as the predictors of 
fibrinolytic success [6, 7]. We studied the clinical profile 
of the patients presenting with PHVT undergoing 
fibrinolytic therapy. As, the NYHA functional 
classification is used to describe the severity of clinical 
status in patients with heart failure with dyspnea and/or 
angina, the main aim of this study is to evaluate the 
patients of PHVT with respect to NYHA functional 
class on presentation and its association with outcome 
of fibrinolytic therapy. 
MATERIALS AND METHODS 
This was a prospective, observational study conducted 
in the department of cardiology at our institute, from 
June, 2016 to April, 2018. Total 133 patients with 
PHVT were enrolled. The study was approved by 
institutional ethics committee. We prospectively 
enrolled the data of patients admitted with valve 
replacement and having history suggestive of prosthetic 
valve dysfunction in form of recent onset acute or 
subacute dyspnea (< 1 month) or embolic phenomena 
were subjected to evaluate for prosthetic heart valve 
thrombosis. Patients with confirmed diagnosis of valve 
thrombosis either by transthoracic/transesophageal 
echocardiography or cine-fluoroscopy were included in 
our study. Patients with gradual or chronic history 
suggestive of valve dysfunction were excluded. Patients 
with prosthetic valve endocarditis were also excluded. A 
written informed consent was taken from all the 
subjects.  
Routine blood investigations included complete 
hemogram, liver and renal function tests. Prothrombin 
time with INR was done on admission and previous 
record of anticoagulation was noted if available. On 
admission, detailed transthoracic echo evaluation was 
performed. For mitral prostheses, a mean gradient > 10 
mm Hg and an effective area (< 1 cm2) was indicative of 
PHVT. For aortic prostheses, criterion for PHVT was a 
mean gradient > 45 mm Hg. Serial echocardiography 
was performed after fibrinolytic therapy to evaluate 
resolution of thrombus and transprosthetic valve 
gradient. 
In fibrinolytic therapy all details of fibrinolytic therapy 
were noted (e.g. fibrinolytic agent, dose, duration, 
complications, etc.). Streptokinase (SK) and Urokinase 
(UK) have been the most used fibrinolytic agents. 
Patients with known allergy to SK or those who have 
been exposed previously to SK were given UK. 
Fibrinolytic Regimen 
Streptokinase: 250,000-U bolus given in 30 min, 
followed by an infusion of 100,000 U/h. 
Urokinase: 4,400 U/kg bolus over 30 min followed by 
4400 U/kg per hour 
Statistical Analysis 
All statistical studies were carried out using IBM SPSS 
program vs 20. Quantitative variables were expressed as 
the mean ± standard deviation and qualitative variables 
were expressed as percentage (%). Parametric values 
between two groups were performed using the 
independent sample t-test or chi-square test, as 
appropriate. Univariate and multivariate logistic 
regression was used to find out factors associated with 
outcome. Categorical variables were compared using 
the chi-square test. A nominal significance was taken as 
a two tailed p value < 0.05.  
RESULTS 
The study population consisted of 45 (33.8%) males 
and 88 (66.2%) females, with mean age of 38.4 ± 12.4 
years. Range of average hospital stay of 117 discharged 
patients was 4-29 days with mean 11.05 days. The mean 
interval between the first implantation and valve 
thrombosis was 25.2 months (range 64 days to 11 
years). The baseline characteristics of the study are 
mentioned in Table 1.  
Every patient was tested on admission for prothrombin 
time and INR. Out of 133 patients 90 patients (67.7%) 
were inadequately anticoagulated on admission while 
43 (32.3%) patients admitted with adequate 
anticoagulation. Each patient underwent detailed 
transthoracic echocardiography evaluation and was 
evaluated serially for treatment monitoring. Majority of 
patients (69.2%) had dilated left atrium on admission. 
73.8% of patients had good LV function, only 12.4% 
patients had moderate to severe LV dysfunction. 
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Around 44.6% patients had moderate to severe PAH on 
admission. Transthoracic 2D echocardiography was 
done in all 133 patients, additionally cine-fluoroscopy 
and transesophageal echocardiography were used in 93 
(71.5%) and 9 (6.9%) patients, respectively. In 23 
(17.8%) patients, both cine-fluoroscopy and 
transesophageal echocardiography were used in 
addition to trans thoracic echocardiography. The TEE 
was more helpful to rule out pannus formation or non-
thrombotic causes for prosthetic valve dysfunction. 
Atrial fibrillation or flutter was present in 36.9% patients 
and remaining 63.1% had sinus rhythm. On 
presentation, 48.9% patients were in NYHA class III, 
41.4% in NYHA class IV and 9.8% in NYHA class II. 
Mortality in NYHA class II was 0%, NYHA class III 4.6% 
and in NYHA class IV 23.6%. 
Thrombosis in valves included 103 (77.4%) bi-leaflet 
valves, 29 (21.8%) tilting disc valves and 1 (0.8%) ball 
cage valve. 98 (73.7%) patients had history of MVR, 13 
(9.7%) had history of AVR, 20 (15.0%) had history of 
DVR (mitral and aortic) and 2 (1.5%) patients had TVR 
(mitral, aortic, and tricuspid). Of 20 patients with DVR, 
15 had mitral valve thrombosis and 5 had aortic valve 
thrombosis. Of TVR patients, both had tricuspid valve 
thrombosis.  
All patients received fibrinolytic therapy of which 108 
(81.2%) were treated with streptokinase and 25 
(18.8%) were treated with urokinase. Duration of 
fibrinolytic therapy ranged from 1-48 hours. Average 
duration of fibrinolytic therapy was 33.09 hours. 
Fibrinolytic therapy was successful in 105 patients 
(78.9%) and it failed in 28 patients (21.1%). In hospital 
mortality was 12.03 % (16 patients), 12 patients went for 
redo surgery after failure of fibrinolytic therapy. 
Mortality was significantly higher in NYHA class IV 
(23.6%) patients compared to class II or III patients (P 
= 0.007 and 0.04, respectively). Thus, NYHA functional 
class was found to be strong independent predictor of 
outcome of patient irrespective of treatment modality. 
Successful fibrinolytic therapy was achieved in 100% 
patients with NYHA class II, 89.2% in NYHA class III 
and 61.8% in NYHA class IV.  After treatment only 8.7% 
patients had residual moderate PAH. Total 117 patients 
were followed up to 6 months after discharge. Out of 
117, 12 (11.4%) patients developed recurrence of 
PHVT. 
In univariate analysis, factors associated with mortality 
were complications and NYHA functional class (P = 
0.002) (Table 2). In NYHA class III group, 3 patients 
developed complications, of which one patient 
developed hypersensitivity reaction to streptokinase 
and 2 patients developed hemorrhagic complications. 
One patient developed intra cerebral hemorrhage and 1 
developed gum bleeding. In NYHA class IV group, total 
13 patients developed complications. Six patients 
developed cardio-embolic complications of which 4 
patients developed TIA/stroke, and 2 patients 
developed peripheral embolization. Hemorrhagic 
events were seen in 7 patients with NYHA class IV 
group, of which 5 patients developed intra cerebral 
hemorrhage, 1 patient developed hematuria and 1 
patient developed epistaxis. No association was 
observed with age, sex, palpitation, and valve type. In 
multivariate analysis, by logistic regression the only 
factor associated with mortality was NYHA functional 
class (95% CI -0.23 to -0.07, P = 0.0001). 
 
Table 1. Baseline Characteristics 
Parameters N=133(%) 
Age, years 38.4 ± 12.4 
Sex  
Male 45 (33.8) 
Female 88 (66.2) 
Type of Prosthetic valve  
Bileaflet 103 (77.4) 
Tilting disc 29 (21.8) 
Ball cage 1 (0.8) 
NYHA class  
Class-II 13 (9.77) 
Class-III 65 (48.87) 
Class-IV 55 (41.35) 
Cardiac rhythm  
Sinus 84 (63.16) 
Atrial fibrillation 49 (36.84) 
Inadequate anticoagulation 90 (67.67) 
Fibrinolytic agent  
Streptokinase 108 (81.2) 
Urokinase 25 (18.8) 
Data in table are presented as Mean ± SD or No. (%) 
 
Table 2. Distribution According to NYHA Class 
Variables NYHA Class-II n = 13 (%) NYHA Class-III n = 65 (%) NYHA Class-IV n = 55 (%) P Value 
Age, years 35.1 ± 16.7 37.5 ± 12.8 39.9 ± 12.6 0.39 
Male 3 (23.1) 22 (33.8) 20 (36.4) 0.75 
Female 10 (76.9) 43 (66.2) 35 (63.6) 0.66 
Complication 0 3 (4.6) 13 (23.6) 0.002* 
Failed fibrinolysis 0 7 (10.8) 21 (38.2) 0.0002* 
Discharge 13 (100) 62 (95.4) 42 (76.4) 0.002* 
*P-value < 0.05 shows statistical significance 
Data in table are presented as Mean ± SD or No. (%) 
 
DISCUSSION 
Majority of patients in our study were relatively young. 
Around 60% patients were below 40 years of age. 
Reason for this is high prevalence of rheumatic heart 
disease (RHD) in young patients in our country and 
that’s why majority of patients undergoing valve 
replacement are relatively young compared to 
developed countries. Many studies from India have 
shown that females are more predisposed to PHVT [8]. 
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The most common risk factors leading to development 
of PHVT are inadequate anticoagulation, atrial 
fibrillation, left ventricular dysfunction, early post-
operative period and pannus or vegetation [9]. The 
occurrence of PHVT is higher in left sided valves, mitral 
valve than aortic valve. Present study showed mitral 
prosthesis was most involved (73.7%) followed by AVR 
(9.8%). In a study by Gupta et al, 87.3% of the PHVT 
episodes occurred in the mitral position. Several studies 
have confirmed that mitral PHVT is twice or thrice 
more frequent than an aortic PHVT [8, 10].  
In this study, overall, 90 (67.7%) patients showed 
inadequate anticoagulation. Similar observations were 
also found in studies conducted in developing countries 
such as Cuba and Nepal where the rates of inadequate 
anticoagulation were high (75% and 69.6%, 
respectively) [11, 12]. Other studies from India showed 
variable rates of inadequate anticoagulation ranging 
from 41.5% to 90.3% [13]. Streptokinase was the most 
used (81.2%) agent for fibrinolysis. The remaining 25 
(18.8%) patients were treated with urokinase. Recent 
studies on using fibrinolytic therapy in treating PHVT 
showed favorable results proposing it to be applied as 
the first line of management, however data from any 
randomized controlled trials are deficient [6, 10]. Study 
done by Kathivel et al. used streptokinase compared to 
tenactaplace for left-sided PHVT. Complete success 
rate of fibrinolytic therapy was almost equal in both 
groups (77.5%). The study reported that Tenecteplase 
can be used for fibrinolytic therapy of PHVT in place of 
streptokinase with equivalent efficacy and at the alike 
rate of occurrence of any complication [14]. Present 
study showed similar success rate for streptokinase 
(78.5%).  
Literature states that fibrinolysis has been an 
appropriate alternative to surgery for treatment of 
PHVT in India, which was also found in our study. 
Accordingly, in the recent PHVT guidelines of the 
Society of Heart Valve Disease, fibrinolysis was 
recommended as first-line therapy in all PHVT patients 
having thrombus diameter ≥ 5 mm, irrespective of the 
obstruction and NYHA functional class, and surgery 
must be reserved only for patients with failed fibrinolysis 
or in patients who indicate contraindication to 
fibrinolysis [2]. Another guideline, American College of 
Chest Physicians suggests fibrinolysis to be considered 
as the first choice for PHVT with thrombus burden <0.8 
sq.cm; regardless of NYHA class [15]. Recently, the 
updated American College of Cardiology/American 
Heart Association guidelines report that choice of 
fibrinolysis or surgery should be dependent on multiple 
factors such as NYHA class, thrombus burden, 
contraindications to fibrinolysis, surgical risk, and 
recurrence [4].  
Fibrinolysis possess various benefits like simplicity, easy 
availability, and comparative low cost. The success rate 
upon application of fibrinolysis has been variable as 
reported by previous Indian studies. It ranged from 59% 
to 100%, with an average rate of 78.1% success. 
However, the mortality rate was found to be between 
1.9% and 9.5%. The incidences of major complications 
due to fibrinolysis included thromboembolism, major 
bleed, and anaphylaxis (8.4% to 18.7%) while minor 
complications included minor bleed, fever, etc. (2.3% to 
25%) [10, 14, 16-18]. Present study supports the 
previous study reports; complete success in fibrinolytic 
therapy was observed in 101 patients (75.9%), with 
13.2% complications and in-hospital mortality.  
Present study showed total 133 patients with fibrinolytic 
therapy, complete clinical success achieved in 100% 
patients with NYHA class II, 89.2% in NYHA class III 
and 61.8% in NYHA class IV. We observed 12.0% 
mortality and 11.4% recurrence during follow up. From 
12 patients (11.4%) who developed recurrence of 
PHVT, seven underwent surgery, five were given 
urokinase; one patient expired in surgical group and 
three patients expired in urokinase group. Most of the 
patients who died presented with NYHA class-IV (N = 
13). As compared to other studies, the relatively high 
mortality rate due to majority (92.3%) of patients 
presenting in NYHA class III/IV. Study done by Nawale 
et al. also had small sample size but the patients 
presenting with NYHA class III and IV in that study 
were 38.1% and 52.4%, respectively [13]. In 2009, study 
of 68 patients’ fibrinolytic success was achieved in 85% 
of patients, with an equally high success rate of 80% 
among NYHA class IV and class III patients; which 
correlates to present study. Recurrence rate was high 
(22%) than present study [19]. Similarly, One Indian 
study conducted by Patil et al. achieved 90.5% successful 
fibrinolytic therapy with 5.7% mortality [8]. 
Complications of fibrinolytic therapy, redo surgery, and 
failed fibrinolysis were frequently seen in NYHA class 
IV. In hospital mortality was also significantly higher in 
patients with NYHA class IV. These findings confirm 
that NYHA functional class is an important predictor of 
outcomes. 
CONCLUSION 
Considering results from our single center experience, 
fibrinolytic therapy can be considered as an effective first 
line therapy for prosthetic heart valve thrombosis. 
Moreover, the NYHA functional class on presentation 
can predict the outcome of fibrinolytic therapy. 
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